Literature DB >> 22593484

Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myeloma.

Lisa Billecke1, Eva Maria Murga Penas, Annette M May, Monika Engelhardt, Arnon Nagler, Merav Leiba, Ginette Schiby, Nicolaus Kröger, Jozef Zustin, Andreas Marx, Jakob Matschke, Markus Tiemann, Eray Goekkurt, Carsten Bokemeyer, Georgia Schilling.   

Abstract

BACKGROUND: Extramedullary (EM) organ impairment in patients with multiple myeloma (MM) is a rare event, occurring mostly during disease relapse after high-dose chemotherapy with autologous or allogeneic stem cell transplantation. This manifestation is commonly associated with an unfavourable outcome. Previous studies suggested a correlation between the clinical course of patients with MM and EM and the cytogenetic findings, e.g. deletion of TP53 on 17p13.
MATERIALS AND METHODS: We investigated patients with these rare plasma cell organ infiltrations (n=17) as well as bone lesions or soft tissue lesions, known to be a common clinical feature of MM (n=14), using a newly established method of fluorescence in situ hybridization in combination with cytoplasmic immunoglobulin staining (cIg-FISH) on paraffin-embedded sections and a specific probe for TP53 on 17p13. RESULTS AND
CONCLUSION: The incidence of del(17)(p13) was similar in both groups but overall it was higher when compared to published data obtained from bone marrow samples and material originating from osteolyses. Further investigations on a larger patient cohort are needed in order to confirm these findings.

Entities:  

Mesh:

Year:  2012        PMID: 22593484

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Extramedullary manifestation in multiple myeloma bears high incidence of poor cytogenetic aberration and novel agents resistance.

Authors:  Xiaoyan Qu; Lijuan Chen; Hairong Qiu; Hua Lu; Hanxin Wu; Hongxia Qiu; Peng Liu; Rui Guo; Jianyong Li
Journal:  Biomed Res Int       Date:  2015-04-23       Impact factor: 3.411

Review 2.  p53 abnormalities and potential therapeutic targeting in multiple myeloma.

Authors:  P J Teoh; W J Chng
Journal:  Biomed Res Int       Date:  2014-06-17       Impact factor: 3.411

3.  Oral lesion as unusual first manifestation of multiple myeloma: case reports and review of the literature.

Authors:  A Romano; M S Marescalco; Chiara Liardo; L Villari; C Vetro; C Conticello; F Di Raimondo; S Ferlito
Journal:  Case Rep Hematol       Date:  2014-11-25

4.  Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma.

Authors:  M Martello; A Poletti; E Borsi; V Solli; L Dozza; S Barbato; E Zamagni; P Tacchetti; L Pantani; K Mancuso; I Vigliotta; I Rizzello; S Rocchi; S Armuzzi; N Testoni; G Marzocchi; G Martinelli; M Cavo; C Terragna
Journal:  Blood Cancer J       Date:  2022-01-26       Impact factor: 11.037

5.  Recurrent plasmacytomas after allografting in a patient with multiple myeloma.

Authors:  Allen N Stawis; Diane Maennle; Moreno Festuccia; Zia Uddin; Benedetto Bruno
Journal:  Case Rep Med       Date:  2012-12-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.